Pharmacoeconomics and Pharmaceutical Economics Commons^™

Surgical And Transcatheter Pulmonary Valve Replacement In Patients With Congenital Heart Disease, Who Have A History Of Right Ventricular Outflow Tract Remodeling, Indonesia: A Model-Based Economic Evaluation, Andi Nurul Annisa, Puree Anantachoti, Radityo Prakoso, Dafsah A. Juzar, Osot Nerapusee

The Thai Journal of Pharmaceutical Sciences

Background: Patients with congenital heart disease who have previously undergone right ventricular outflow tract (RVOT) surgery frequently require repeat valve replacement later in life. While transcatheter pulmonary valve replacement (TPVR) offers less invasive reintervention compared with surgery, its high device cost raises concerns about affordability under Indonesia’s National Health Insurance Program (Jaminan Kesehatan Nasional).
Objectives: To compare the cost-effectiveness of surgical pulmonary valve replacement (SPVR) versus TPVR in post-RVOT surgery patients, and to estimate the TPVR price threshold for cost-effectiveness from a societal perspective.
Methods: A Markov model simulated a hypothetical cohort of 15-year-old patients with prior RVOT surgery over …

Pharmacogenetic-Guided Antiplatelet Therapy For Personalized Medicine In Patients With Stroke And Transient Ischemic Attack Without Cardioembolic Stroke: A Systematic Review Of Economic Evaluations, Nathapol Samprasit, Chamipa Phanudulkitti, Nattanichcha Kulthanachairojana, Jatapat Hemapanpairoa

The Thai Journal of Pharmaceutical Sciences

Background: Stroke is a major global public health burden. Ischemic stroke is the most common type of all stroke cases worldwide. Antiplatelet therapy is a key strategy for secondary prevention in patients with stroke and transient ischemic attacks (TIAs) without cardioembolic stroke. Dual antiplatelet therapy (DAPT) with clopidogrel is recommended in patients with early mild stroke or high-risk TIA, followed by long-term single antiplatelet therapy (SAPT). Clopidogrel is often used as an alternative for patients with aspirin resistance or intolerance. However, clopidogrel is a prodrug metabolized by the CYP2C19 enzyme, leading to variability in its effectiveness.

Objectives: This study aims …

Cost Effectiveness Analysis Of Enzalutamide, Abiraterone Plus Prednisone And Cabazitaxel Plus Predinsone For The Treatment Of Visceral Metastatic Castration Resistant Prostate Cancer (Mcrpc) After Docetaxel Therapy, Yazan K. Barqawi

Pharmaceutical Sciences ETDs

Background: Prostate cancer is the second leading cause of death after lung cancer among men in the US. The America Cancer Society predicts 164,690 new cases and 29,430 prostate cancer deaths in 2018. Of those diagnosed with prostate cancer, about 10-20 % will develop castration-resistant prostate cancer (CRPC) within 5 years of diagnosis and 70 % of those cases will metastasize to mCRPC. In 2014, nearly US $13.4 billion was spent on prostate cancer in the US and expected to reach US $15.4 billion by 2020; making prostate cancer the fifth most costly cancer.

Objective: To conduct a cost-effective analysis …